Raising awareness of prostate cancer community needs
This Movember, a month dedicated to raising awareness of men’s health issues, we're focused on awareness of prostate cancer—a leading cause of cancer deaths among males.1
Prostate cancer around the world
Despite advancements in care, prostate cancer is the most frequently diagnosed cancer in over 50% of countries (112/185), with more 1.4 million new cases and 375 000 deaths in 2020 alone.2,3
Bringing innovation to this underserved population has the potential to transform how advanced prostate cancer is treated.
At Novartis, we are driving forward new research for males living with advanced prostate cancer. Hear from Dr. Susanne Schaffert, President of Novartis Oncology; Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development; and Dr Andrew Cavey, Global Program Head, Prostate Cancer for Advanced Accelerator Applications (AAA), a Novartis Company, on the need for continued discussions about men’s health and Novartis’ commitment to the prostate cancer community.
Reimagining outcomes for males
We’re committed to advancing care for males with prostate cancer through new research aimed at delivering hope. We’re developing an emerging form of nuclear medicine called targeted radioligand therapy. This exciting precision medicine may have potential in the treatment of advanced prostate cancer.